SEC Form 4 · accession 0000874015-18-000018
IONIS PHARMACEUTICALS INC · IONS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stanley T Crooke
Officer — Chairman and CEO · Director
Period of report
Jan 15, 2018
Accepted (ET)
Jan 17, 2018 · 9:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874015
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 15, 2018 | M | 29,612 | $0.00 | A | 67,626 | D | |
| Common StockF2 | Jan 15, 2018 | S | 15,893 | $51.76 | D | 51,733 | D | |
| Common StockF1 | Jan 15, 2018 | M | 1,722 | $0.00 | A | 4,784 | I | By wife |
| Common StockF2,F3 | Jan 15, 2018 | S | 656 | $51.76 | D | 4,128 | I | By wife |
| Common Stock | holding | — | — | — | 725,391 | I | By trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF4,F5,F6 | — | Jan 15, 2018 | A | 35,149 | A | — | — | Common Stock | 35,149 | 35,149 | D |
| Restricted Stock UnitsF5,F7,F6 | — | Jan 15, 2018 | A | 3,911 | A | — | — | Common Stock | 3,911 | 3,911 | I |
| Restricted Stock UnitsF5,F6 | — | Jan 15, 2018 | M | 29,612 | D | — | — | Common Stock | 29,612 | 43,515 | D |
| Restricted Stock UnitsF5,F6 | — | Jan 15, 2018 | M | 1,722 | D | — | — | Common Stock | 1,722 | 3,047 | I |
Explanation of responses
- F1Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.
- F2The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.759 to $51.768, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
- F4Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan.
- F5Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
- F6Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.
- F7Grant to reporting person's wife of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan.